iVeena Patents

Patent portfolio assigned to iVeena (verified via public assignee records). Active clinical-stage ophthalmology company (eye-drop drug delivery) spun out of the Univ. of Utah Moran Eye Center. Glaukos exclusively licensed lead asset IVMED-80 for keratoconus ($10M upfront, Aug 2022) - treated as a partner relationship, not a paying customer. Patents confirmed as assignee (e.g. US20210060059A1 'Treatment of myopic progression'; 2017 Notice of Allowance for IVMED-10/20); exact count not confirmed.